RESUMO
Systemic lupus erythematosus juvenile (SLEJ) is a multi-systemic, chronic inflammatory disease, and with autoimmune features. Some clinical manifestations of this disease are similar to those found in Acquired Immunodeficiency Syndrome (AIDS). Coexistence of AIDS with SLEJ is rare, especially in the pediatric population, being described in the literature just 5 patients with congenital HIV infection who developed this rheumatological condition, presenting lupus nephritis as the initial manifestation. We report the case of a 14 year old patient, diagnosed with HIV infection at 8 months of age, with signs and symptoms of SLEJ. This report aims to describe a female patient with AIDS who developed SLE in its classic and forms, but has evolved satisfactorily.
Assuntos
Síndrome da Imunodeficiência Adquirida/complicações , Lúpus Eritematoso Sistêmico/etiologia , Adolescente , Feminino , HumanosRESUMO
O lúpus eritematoso sistêmico juvenil (LESJ) é uma doença inflamatória crônica, multissistêmica e autoimune. Algumas manifestações clínicas dessa condição são semelhantes às encontradas na síndrome da imunodeficiência adquirida (SIDA). A coexistência da SIDA com o LESJ é rara, especialmente na população pediátrica, sendo descritos na literatura pesquisada apenas cinco casos de pacientes com infecção congênita por HIV que desenvolveram essa enfermidade reumatológica, tendo como manifestação inicial a nefrite lúpica. Relata-se o caso de uma paciente de 14 anos, com diagnóstico de infecção pelo HIV aos 8 meses de idade, na qual se realizou diagnóstico de LESJ com base nos critérios diagnósticos do Colégio Americano de Reumatologia. Este relato tem a finalidade de descrever uma paciente com SIDA que, embora tenha desenvolvido LESJ em sua forma clássica e grave, evoluiu satisfatoriamente.
Systemic lupus erythematosus juvenile (SLEJ) is a multi-systemic, chronic inflammatory disease, and with autoimmune features. Some clinical manifestations of this disease are similar to those found inAcquired Immunodeficiency Syndrome (AIDS). Coexistence of AIDS with SLEJ is rare, especially in the pediatric population, being described in the literature just 5 patients with congenital HIV infection who developed this rheumatological condition, presenting lupus nephritis as the initial manifestation. We report the case of a 14 year old patient, diagnosed with HIV infection at 8 months of age, with signs and symptoms of SLEJ. This report aims to describe a female patient with AIDS who developed SLE in its classic and forms, but has evolved satisfactorily.
Assuntos
Adolescente , Feminino , Humanos , Síndrome da Imunodeficiência Adquirida/complicações , Lúpus Eritematoso Sistêmico/etiologiaRESUMO
Propylthiouracil (PTU), a thyonamide class drug commonly used to treat hyperthyroidism has been reported to cause adverse reactions in 3% to 12% of patients. The side effects have been described more frequently as mild, but ocasionally severe fatal reactions may occur. We report the case of a fourteen years old patient in use of PTU for the last three years who presented with fever, hemorrhagic blisters, necrotic ulcers, and that developed purpuric lesions and nodules in lower extremities. Laboratory and histopathologic findings were compatible with skin leukocytoclastic vasculitis, a pattern found in hypersensitivity reaction vasculitis. Suspension of PTU and introduction of prednisone, induced complete remission of symptoms and healing of the skin lesions. The importance of this study is to call attention to the occurrence of serious cutaneous manifestation with a mortality rate that might reach 10%, associated with a systemic drug frequently used in internal medicine. Early diagnosis and withdrawal of the suspected medication is mandatory. Administration of corticosteroids and/or immunosuppressives agents must be considered.
Assuntos
Antitireóideos/efeitos adversos , Propiltiouracila/efeitos adversos , Vasculite Leucocitoclástica Cutânea/induzido quimicamente , Adolescente , Humanos , Masculino , Necrose , Prednisona/uso terapêutico , Propranolol/uso terapêutico , Vasculite Leucocitoclástica Cutânea/patologiaRESUMO
O propiltiouracil (PTU), droga empregada no tratamento do hipertireoidismo, pode provocar reações adversas em 3 por cento a 12 por cento dos pacientes, desde reações leves e frequentes, até quadros incomuns, graves e fatais. Relata-se o caso de um paciente de 14 anos de idade, em uso de PTU há três anos, que apresentou febre, bolhas hemorrágicas e úlceras necróticas, evoluindo com lesões purpúricas e nódulos violáceos em membros inferiores. A avaliação laboratorial e histológica mostrou-se compatível com vasculite cutânea leucocitoclástica, padrão encontrado nas vasculites por reação de hipersensibilidade. Após a retirada da droga antitireoidiana e a introdução de prednisona, houve regressão progressiva das lesões cutâneas. A importância deste estudo é alertar sobre a ocorrência desta grave manifestação cutâneo-sistêmica (vasculite), por droga de uso frequente em medicina interna, cuja taxa de mortalidade é de 10 por cento. É obrigatório o diagnóstico precoce, visando à retirada da droga suspeita, e, se necessário, ao uso de corticosteroides e/ou imunossupressores.
Propylthiouracil (PTU), a thyonamide class drug commonly used to treat hyperthyroidism has been reported to cause adverse reactions in 3 percent to 12 percent of patients. The side effects have been described more frequently as mild, but ocasionally severe fatal reactions may occur. We report the case of a fourteen years old patient in use of PTU for the last three years who presented with fever, hemorrhagic blisters, necrotic ulcers, and that developed purpuric lesions and nodules in lower extremities. Laboratory and histopathologic findings were compatible with skin leukocytoclastic vasculitis, a pattern found in hypersensitivity reaction vasculitis. Suspension of PTU and introduction of prednisone, induced complete remission of symptoms and healing of the skin lesions. The importance of this study is to call attention to the occurrence of serious cutaneous manifestation with a mortality rate that might reach 10 percent, associated with a systemic drug frequently used in internal medicine. Early diagnosis and withdrawal of the suspected medication is mandatory. Administration of corticosteroids and/or immunosuppressives agents must be considered.